TNFRSF9 and melanoma: Balakrishnan et al. developed a novel treatment for melanoma combining PBNPs mediated PTT with agonistic anti-CD137 monoclonal antibody (mAB) therapy to reverse T cell immunosuppression and complement PTT-induced ICD effects in order to elicit a strong antitumor immune response.